RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance

U.S. Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
32.70-0.04 (-0.13%)
At close: 3:59PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close32.74
Bid0.00 x
Ask0.00 x
Day's Range32.54 - 36.82
52 Week Range25.25 - 36.82
Avg. Volume1,175,301
Market Cap223.5B
PE Ratio (TTM)23.45
Earnings DateN/A
Dividend & Yield1.02 (3.16%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AstraZeneca Wallops Profit Views Despite Toppling Sales; Eyes Key Trial
    Investor's Business Daily3 days ago

    AstraZeneca Wallops Profit Views Despite Toppling Sales; Eyes Key Trial

    The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.

  • The Wall Street Journal3 days ago

    [$$] Roche Revenue Up 4%

    Roche Holding said revenue rose in the first quarter, thanks to strong sales of several of its drugs.

  • Reuters3 days ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.